• Heidelberg Pharma will present HDP-101 and HDP-102 clinical data at the ASH annual meeting in New Orleans, December 12-15, 2026.
• HDP-101 showed consistent clinical activity with a favorable safety profile in heavily pretreated patients with relapsed or refractory multiple myeloma.
• The HDP-101 dose-escalation phase ended in April 2026; the Phase IIa expansion is progressing as planned.
• Early HDP-102 treatment was well tolerated, with signs of biological activity, including disease stabilization and lymph node reduction.
• Partnership opportunities are being explored to continue HDP-102 following the September 2025 decision to discontinue its study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Heidelberg Pharma AG published the original content used to generate this news brief via EQS News (Ref. ID: corporate_2428588_en) on November 04, 2026, and is solely responsible for the information contained therein.